Related coverage linked through entity extraction aliases.
Aug 19, 2026
New research shows GLP-1 receptor agonists are associated with reduced asthma exacerbation risk in overweight, obese, and morbidly obese patients without diabetes, with risk reductions of 14.6%, 12.2%, and 13.3% respectively. The findings were presented at the 2026 AAAAI Annual Meeting.
Aug 08, 2026
Physician-supervised clinics in Florida and Texas offer semaglutide and tirzepatide weight loss programs. Clinical trials show average weight loss of 15% with semaglutide and about 21% with tirzepatide. All-inclusive monthly plans start at $349.
May 06, 2026
Nereus (tradipitant) is now commercially available for prevention of motion-induced vomiting. Vanda has launched a phase 3 trial in GLP-1 users, building on phase 2 results showing a 50% relative reduction in vomiting.
Jul 25, 2026
The UK MHRA approved oral semaglutide (Wegovy) as the first GLP-1 weight loss tablet on 11 June 2026. A new report links high-dose tirzepatide to anhedonia, and data show bariatric surgery declining sharply as GLP-1 use surges.
Aug 08, 2026
Orforglipron beat oral semaglutide on blood sugar and weight in type 2 diabetes, with higher discontinuation rates. GLP-1 hair loss is typically temporary telogen effluvium.
Jul 28, 2026
GLP-1 receptor agonists are linked to a higher risk of smell and taste disturbances, while poison control calls involving semaglutide have soared since 2021. The drugs produce significant weight loss and are reshaping U.S. food demand, with roughly one in eight adults now taking them.
Aug 01, 2026
One in eight U.S. adults now takes a GLP-1, and prescriptions among non-diabetics rose 700% since 2019. The market is projected to reach $200 billion by 2030, driving manufacturing investments and consumer food shifts.
Aug 04, 2026
Semaglutide may lower risks of adult-onset seizures and alcohol-related hospitalizations, new studies find. Brazil approved five semaglutide injectables, and a commentary updates obesity care with GLP-1 drugs.
Jun 19, 2026
Novo Nordisk is phasing out Rybelsus and introducing a newer oral semaglutide formulation as the Ozempic pill, which requires a new prescription and lower doses. Generic semaglutide from Dr. Reddy's and Apotex is entering Canada, prompting Novo Nordisk to cut Ozempic prices for some patients without coverage. GoodRx and Novo Nordisk also launched self-pay pricing for oral Ozempic starting at $149 per month.
Jul 17, 2026
Aptar Pharma published three patent applications for GLP-1 inhaled/nasal delivery and launched a system-level injectable development framework. Preclinical data showed up to 10x higher semaglutide Cmax.
Jul 21, 2026
The FDA moved to exclude semaglutide, tirzepatide and liraglutide from its 503B compounding list. Eli Lilly won U.S. approval for its oral pill Foundayo, and Novo Nordisk sued Lilly over allegedly misleading weight-loss ads.
Aug 01, 2026
West Pharmaceutical Services beat Q2 estimates with revenue of $872.3 million and raised full-year guidance, driven by GLP-1 and high-value product demand. The stock is up 32.9% year to date, and Wolfe Research upgraded the shares to Outperform with a $375 price target.
Mar 21, 2026
Zydus Lifesciences launched its Semaglutide injection in India after DCGI approval for diabetes and obesity. The product is sold under three brands with a reusable multi-dose pen at about Rs 2,200 per month.
Jun 20, 2026
Amgen shares have fallen 12.6% in three months despite relatively solid Q1 results, while Novo Nordisk maintains a 54.6% global GLP-1 market share. Both companies face pipeline competition and pricing pressures.
Jul 27, 2026
AstraZeneca Q2 core EPS of $2.63 beat consensus, driven by 15% oncology and 8% rare disease growth. The company maintained its 2030 $80 billion revenue target and has more than 20 Phase III readouts expected over the next 18 months.
Jul 25, 2026
Eli Lilly builds $1.5B stockpile for oral obesity drug orforglipron; study shows GLP-1s cut cancer risk; logistics firms invest in cold chain; and amylin drug race heats up with $19B in deals.
Jul 24, 2026
Eli Lilly will file its triple-agonist obesity drug retatrutide in early 2027 via a Biologics License Application, seeking stronger market protections. Positive Phase 3 results showed up to 22.6% weight loss, while cardiovascular safety data raised some questions.
Jul 23, 2026
A recent global analysis shows oncology dominates clinical trial activity in 2025, while Phase II attrition rates dropped to 26%—the lowest in four years. The US remains the leader in investigator sites, but China is the fastest-growing market. Obesity research is poised to break into the top five most-studied diseases.
Jul 22, 2026
The FDA proposes to remove three GLP-1 drugs from the bulk compounding list as adverse events near 2,000 and Senator Tom Cotton demands a probe into Chinese APIs in compounded meds. Shortages have largely resolved, but safety and innovation concerns persist.
Jun 19, 2026
AstraZeneca is advancing its oral GLP-1 drug into Phase III trials while defending dapagliflozin patents in Australia. The company obtained an Australian court injunction against a generic competitor and has partnered with Evinova to use AI for clinical trials. India could be a future market for the oral GLP-1 drug pending global trial data.
